Ignite Creation Date:
2025-12-24 @ 10:30 PM
Ignite Modification Date:
2026-05-17 @ 2:21 PM
Study NCT ID:
NCT00720135
Status:
COMPLETED
Last Update Posted:
2015-06-08
First Post:
2008-07-19
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma
Sponsor:
City of Hope Medical Center
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Anaplastic Large Cell Lymphoma | View |
| None | Cutaneous B-cell Non-Hodgkin Lymphoma | View |
| None | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | View |
| None | Intraocular Lymphoma | View |
| None | Nodal Marginal Zone B-cell Lymphoma | View |
| None | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma | View |
| None | Recurrent Adult Grade III Lymphomatoid Granulomatosis | View |
| None | Recurrent Grade 1 Follicular Lymphoma | View |
| None | Recurrent Grade 2 Follicular Lymphoma | View |
| None | Recurrent Marginal Zone Lymphoma | View |
| None | Small Intestine Lymphoma | View |
| None | Splenic Marginal Zone Lymphoma | View |
| None | Testicular Lymphoma | View |
| None | Waldenstrom Macroglobulinemia | View |
Keywords: